NCT00840606View on ClinicalTrials.gov

Buspirone Hydrochloride 30mg Tablets, Fasting

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

December 31, 2001

Primary Completion Date

December 31, 2001

Study Completion Date

April 30, 2002

Conditions
Healthy
Interventions
DRUG

BUSPAR® 30 mg Tablet

1 x 30 mg, single-dose fasting

DRUG

Buspirone Hydrochloride 30 mg Tablet

1 x 30 mg, single-dose fasting

Trial Locations (1)

58104

PRACS Institute, Ltd., Fargo

All Listed Sponsors
lead

Teva Pharmaceuticals USA

INDUSTRY

NCT00840606 - Buspirone Hydrochloride 30mg Tablets, Fasting | Biotech Hunter | Biotech Hunter